<DOC>
	<DOCNO>NCT00068302</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy sirolimus use different way stop cancer cell divide stop grow die . PURPOSE : This phase I trial study side effect best dose sirolimus treat young patient relapse refractory acute leukemia non-Hodgkin 's lymphoma .</brief_summary>
	<brief_title>Sirolimus Treating Young Patients With Relapsed Refractory Acute Leukemia Non-Hodgkin 's Lymphoma</brief_title>
	<detailed_description>OBJECTIVES : - Determine maximum tolerate dose sirolimus pediatric patient refractory relapse acute leukemia non-Hodgkin 's lymphoma . - Determine dose-limiting toxic effect drug patient . - Determine trough level produce drug patient . - Determine anti-leukemia/lymphoma activity drug patient . OUTLINE : This open-label , dose-escalation study . Patients receive oral sirolimus daily day 1-21 . Courses repeat every 21 day absence disease progression unacceptable toxicity . Cohorts 3-6 patient receive escalate dos sirolimus maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 3 2 6 patient experience dose-limiting toxicity . Patients follow survival . PROJECTED ACCRUAL : A total 3-30 patient accrue study within 2 year .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm diagnosis 1 following : Acute lymphoblastic leukemia ( ALL ) OR acute myeloid leukemia ( AML ) At least 25 % blast bone marrow Recurrent refractory disease NonHodgkin 's lymphoma ( NHL ) Second great relapse determine physical radiological evidence Disease known curative therapy PATIENT CHARACTERISTICS : Age 21 Performance status Karnofsky 50100 % ( patient 10 year age ) Lansky 50100 % ( patient 10 year age ) Life expectancy At least 4 week Hematopoietic Absolute neutrophil count least 1,000/mm^3* Platelet count least 75,000/mm^3 ( transfusion independent ) * Hemoglobin least 8.0 g/dL ( may receive red blood cell ( RBC ) transfusion ) * NOTE : *Patients ALL , AML , NHL tumor metastatic bone marrow , granulocytopenia , anemia , and/or thrombocytopenia eligible , evaluable hematological toxicity Hepatic Bilirubin great 1.5 time normal alanine aminotransferase ( ALT ) great 5 time normal Albumin least 2 g/dL Renal Creatinine base age , follow : No great 0.8 mg/dL ( 5 year age ) No great 1.0 mg/dL ( 6 10 year age ) No great 1.2 mg/dL ( 11 15 year age ) No great 1.5 mg/dL ( 15 year age ) OR Creatinine clearance radioisotope glomerular filtration rate least 70 mL/min Cardiovascular Shortening fraction least 28 % echocardiogram OR Ejection fraction least 50 % gate radionuclide Other Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception Able ingest oral medication No known allergy sirolimus , tacrolimus , mammalian target rapamycin ( mTOR ) inhibitors No uncontrolled active infection Fungal disease must stable least 2 week prior study entry Documented negative blood culture prior study entry patient bacteremia No active graftversushost disease PRIOR CONCURRENT THERAPY : Biologic therapy Recovered prior immunotherapy More 1 week since prior hematopoietic growth factor except epoetin alfa At least 7 day since prior biologic antineoplastic agent At least 3 month since prior bone marrow stem cell transplantation Chemotherapy Recovered prior chemotherapy More 2 week since prior myelosuppressive chemotherapy ( 4 week nitrosoureas ) Prior hydroxyurea within past 2 week allow provided peripheral blast count stable rise least 3 day Endocrine therapy Prior corticosteroid within past 2 week allow provided peripheral blast count stable rise least 3 day Radiotherapy Recovered prior radiotherapy At least 2 week since prior local palliative radiotherapy At least 4 week since prior craniospinal radiotherapy radiation pelvis 50 % At least 4 week since prior substantial bone marrow radiotherapy No concurrent radiotherapy , except emergent situation persistent extramedullary disease resolution bone marrow disease Surgery Not specify Other No concurrent investigational antineoplastic drug No concurrent administration follow : Ketoconazole Tacrolimus Cyclosporine Rifampin Diltiazem</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>21 Years</maximum_age>
	<verification_date>July 2013</verification_date>
	<keyword>recurrent childhood lymphoblastic lymphoma</keyword>
	<keyword>recurrent childhood small noncleaved cell lymphoma</keyword>
	<keyword>recurrent childhood large cell lymphoma</keyword>
	<keyword>recurrent childhood acute myeloid leukemia</keyword>
	<keyword>recurrent childhood acute lymphoblastic leukemia</keyword>
</DOC>